Did You Know...
...When G.G. Hubbard learned of his future son-in-law's invention, he called it "only a toy." His daughter was engaged to a young man named Alexander Graham Bell.
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Application No. | Application Title | Issue Date |
| 20120128669 | MONOVALENT, BIVALENT AND TRIVALENT ANTI HUMAN RESPIRATORY SYNCYTIAL VIRUS (HRSV) NANOBODY CONSTRUCTS FOR THE PREVENTION AND/OR TREATMENT OF RESPIRATORY TRACT INFECTIONS Amino acid sequences are provided that are directed against and/or that can specifically bind protein F of hRSV, as well as to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more such amino acid seque... | 05/24/2012 |
| 20120129766 | METHODS OF TREATING FGF21-ASSOCIATED DISORDERS The invention relates to the identification of new polypeptide and protein variants of fibroblast growth factor 21 (FGF21) that have improved pharmaceutical properties. Also disclosed are methods for treating FGF21-associated disorders, including metabolic conditions.... | 05/24/2012 |
| 20120128664 | GLYCOSYLATED ANTIBODIES The invention provides an antibody comprising human IgG1 or IgG3 heavy chain constant domains that are glycosylated with a sugar chain at Asn297, said antibody being characterized in that the amount of fucose within said sugar chain is at least 99%, and in addition the ... | 05/24/2012 |
| 20120128689 | ANTI-IL-23 IMMUNOGLOBULINS The present invention relates to antigen binding proteins to human IL-23, pharmaceutical formulations containing them and to the use of such antigen binding proteins in the treatment and/or prophylaxis of inflammatory diseases such as Rheumatoid Arthritis (RA).... | 05/24/2012 |
| 20120128704 | REPERTOIRE OF ALLO-RESTRICTED PEPTIDE-SPECIFIC T CELL RECEPTOR SEQUENCES AND USE THEREOF The present invention is directed to a kit-of-parts or composition containing nucleic acid sequences coding for high-avidity, allo-restricted TCR, wherein the TCR are independently directed against the tyrosinase antigen, the melan-A antigen and the survivin antigen. Th... | 05/24/2012 |
| 20120128584 | ANTI-CDH3 ANTIBODIES LABELED WITH RADIOISOTOPE LABEL AND USES THEREOF The present invention relates to anti-CDH3 antibodies, which can be labeled with a radioisotope. Moreover, the present invention provides methods and pharmaceutical compositions that comprise an anti-CDH3 antibody as an active ingredient. Since CDH3 is strongly expresse... | 05/24/2012 |
| 20120128710 | Enhancement of Pathogen-Specific Memory Th17 Cell Responses Compositions and methods for enhancing Th1/Th17 cell responses and decreasing Th2 cell responses are disclosed herein. In various embodiments the present invention describes activation of human dendritic cells and enhancement of antigen-specific T cell responses in a De... | 05/24/2012 |
| 20120128671 | NEUTRALIZING MOLECULES TO INFLUENZA VIRUSES The present invention concerns methods and means for identifying, producing, and engineering neutralizing antibodies against influenza A viruses, and to the neutralizing antibodies produced. In particular, the invention concerns neutralizing antibodies against various i... | 05/24/2012 |
| 20120128692 | HUMAN CYTOMEGALOVIRUS NEUTRALIZING ANTIBODIES AND USE THEREOF The invention relates to neutralizing antibodies, and antibody fragments thereof, having high potency in neutralizing hCMV, wherein said antibodies and antibody fragments are specific for one, or a combination of two or more, hCMV gene UL products. The invention also re... | 05/24/2012 |
| 20120128691 | HUMAN CYTOMEGALOVIRUS NEUTRALIZING ANTIBODIES AND USE THEREOF The invention relates to neutralizing antibodies, and antibody fragments thereof, having high potency in neutralizing hCMV, wherein said antibodies and antibody fragments are specific for one, or a combination of two or more, hCMV gene UL products. The invention also re... | 05/24/2012 |
| 20120128677 | PANCREATIC CANCER TARGETS AND USES THEREOF The present invention provides a method for diagnosing and detecting diseases associated with pancreas. The present invention provides one or more proteins or fragments thereof, peptides or nucleic acid molecules differentially expressed in pancreatic diseases (PCAT) an... | 05/24/2012 |
| 20120128700 | CONSTRUCTS FOR DELIVERY OF THERAPEUTIC AGENTS TO NEURONAL CELLS A non-toxic polypeptide, for delivery of a therapeutic agent to a neuronal cell, comprises a binding domain that binds to the neuronal cell, and a translocation domain that translocates the therapeutic agent into the neuronal cell, wherein the translocation domain is no... | 05/24/2012 |
| 20120128591 | ANTI-FAP ANTIBODIES AND METHODS OF USE The invention provides antibodies against Fibroblast Activation Protein (FAP) and methods of using the same.... | 05/24/2012 |
| 20120128663 | Fc VARIANTS THAT EXTEND ANTIBODY HALF-LIFE The invention relates generally to compositions and methods for altering the serum half-life in vivo of an antibody.... | 05/24/2012 |
| 20120128676 | MUC1 ANTIBODIES The present invention pertains to anti-mucin antibodies having improved antigen binding and/or recognition properties as well as a method for improving the antigen binding and/or recognition of an anti-mucin antibody. In particular, the present invention is directed to ... | 05/24/2012 |
| 20120129759 | PROTEIN SURFACE REMODELING Aggregation is a major cause of the misbehavior of proteins. A system for modifying a protein to create a more stable variant is provided. The method involves identifying non-conserved hydrophobic amino acid residues on the surface of a protein, suitable for mutating to... | 05/24/2012 |
| 20120107324 | TARGETED BINDING AGENTS DIRECTED TO a5ß1 AND USES THEREOF The invention relates to targeted binding agents against α5β1 and uses of such agents. More specifically, the invention relates to fully human monoclonal antibodies directed to α5β1. The described targeted binding agents are useful in the treatment of diseases assoc... | 05/03/2012 |
| 20120107320 | ANTIBODIES SPECIFICALLY DIRECTED TO THE SOLUBLE FORM OF CTLA-4 The invention provides materials and methods relating to antibodies specific for the soluble form of CTLA-4 (sCT-LA-4). Such antibodies have been shown to have a strong boosting effect on antigen-specific human immune responses.... | 05/03/2012 |
| 20120107306 | ANTIBODIES FOR EPIDERMAL GROWTH FACTOR RECEPTOR 3 (HER3) The present invention relates to antibodies or fragments thereof that target a conformational epitope of a HER receptor. In particular, the invention relates to antibodies or fragments thereof that target a conformational epitope of HER3 receptor and compositions and me... | 05/03/2012 |
| 20120107933 | ANTI-MESOTHELIN ANTIBODIES The present invention provides monoclonal anti-mesothelin antibodies and antibody fragments and methods for their use. The antibodies can be completely human.... | 05/03/2012 |
| 20120107233 | Cytotoxicity Mediation of Cells Evidencing Surface Expression of CD44 This invention relates to the diagnosis and treatment of cancerous diseases, particularly to the mediation of cytotoxicity of tumor cells; and most particularly to the use of cancerous disease modifying antibodies (CDMAB), optionally in combination with one or more chem... | 05/03/2012 |
| 20120109097 | RECOMBINANT IL-9 ANTIBODIES AND USES THEREOF The present invention provides novel antibodies that immunospecifically bind to an IL-9 polypeptide and compositions comprising said antibodies. The present invention also provides methods and compositions preventing, treating, managing, and/or ameliorating diseases and... | 05/03/2012 |
| 20120107874 | Modified Host Cells and Uses Thereof The present disclosure provides compositions and methods comprising cells producing glycoproteins with variant glycosylation patterns. The methods and compositions may be used in producing antibodies and proteins of therapeutic value.... | 05/03/2012 |
| 20120082667 | Antibodies That Specifically Bind To A Beta Oligomers And Use Thereof The present inventors successfully produced monoclonal antibodies that are specific to only soluble A beta oligomers, but do not recognize soluble A beta monomers, which are physiological molecules. It was demonstrated that the antibodies are useful as diagnostic/therap... | 04/05/2012 |
| 20120082663 | ANTI-CMET ANTAGONISTS The invention provides therapeutic anti-c-met antibodies, and compositions comprising and methods of using these antibodies.... | 04/05/2012 |
| 20120082670 | CD33 BINDING AGENTS The present invention relates to immunotherapies that are based on myeloid cell depletion. In particular, the present invention relates to CD33 binding agents for use in such therapies, e.g. in the treatment of myeloid cell malignancies and myelodysplastic syndrome (MDS... | 04/05/2012 |
| 20120082673 | HUMAN CYTOKINE RECEPTOR Cytokines and their receptors have proven usefulness in both basic research and as therapeutics. The present invention provides a new human cytokine receptor designated as “Zcytor16.”... | 04/05/2012 |
| 20120082662 | ANTI-CMET ANTAGONISTS The invention provides therapeutic anti-c-met antibodies, and compositions comprising and methods of using these antibodies.... | 04/05/2012 |
| 20120082664 | OPTIMIZED ANTIBODIES THAT TARGET CD19 The present invention describes antibodies that target CD19, wherein the antibodies comprise at least one modification relative to a parent antibody, wherein the modification alters affinity to an FcγR or alters effector function as compared to the parent antibody. Als... | 04/05/2012 |
| 20120082666 | ANTIBODY COMPOSITIONS AND METHODS OF USE The invention provides compositions comprising anti-gH antibodies and anti-Complex I antibodies as well as methods of using the same.... | 04/05/2012 |
| 20120082661 | ANTI-BCMA ANTIBODIES This invention provides antibodies that recognize the B Cell Maturation Antigen (BCMA) and that bind naïve B cells, plasma cells, and/or memory B cells. The invention further provides methods for depleting naïve B cells, plasma cells, and memory B cells, and for treat... | 04/05/2012 |
| 20120084871 | NPC1L1 ORTHOLOGUES The present invention provides, in part, NPC1L1 from various species. Methods of using the NPC1L1 polypeptides and polynucleotide set forth herein, e.g., in screening assays, are also set forth.... | 04/05/2012 |
| 20120083589 | Antibody Modulating The Differentiation And Function Of Dendritic Cells Via Binding Intercellular Adhesion Molecule-1 And Use Thereof The present invention relates to an antibody binding to human intercellular adhesion molecule-1 (ICAM-1) where the antibody is able to modulate the differentiation status of dendritic cells and prolong the graft survival. In addition, the present invention provides a ph... | 04/05/2012 |
| 20120083588 | Neutral amino acid transporter and gene thereof The present invention relates to an amino acid transporter protein having the ability to mediate the transport of amino acids into a cell, a gene encoding the protein, an antibody having a reactivity with the protein, a cell which produces the antibody, related kits and... | 04/05/2012 |
| 20120082693 | USE OF PROTEINS AND PEPTIDES ENCODED BY THE GENOME OF A NOVEL SARS-ASSOCIATED CORONAVIRUS STRAIN The invention relates to the use of proteins and peptides coded by the genome of the isolated or purified strain of severe acute respiratory syndrome (SARS)-associated coronavirus, resulting from sample reference number 031589 and, in particular, to the use of protein S... | 04/05/2012 |
| 20120083442 | MYOSTATIN BINDING AGENTS The present invention provides binding agents comprising peptides capable of binding myostatin and inhibiting its activity. In one embodiment the binding agent comprises at least one myostatin-binding peptide attached directly or indirectly to at least one vehicle such ... | 04/05/2012 |
| 20120082682 | IL-13 BINDING PROTEIN The present invention relates to antigen binding proteins to human IL-13, including anti-IL-13 antibodies and anti-IL-3/anti-IL-4 mAbdAbs, pharmaceutical formulations containing them and to the use of such antigen binding proteins in the treatment and/or prophylaxis of ... | 04/05/2012 |
| 20120082674 | ENTEROCOCCUS ANTIGENS The present invention discloses isolated nucleic acid molecules encoding a hyperimmune serum reactive antigen or a fragment thereof as well as hyperimmune serum reactive antigens or fragments thereof from E. faecalis, methods for isolating such antigens and speci... | 04/05/2012 |
| 20120082681 | ANTI-IL12RBETA1 ANTIBODIES AND THEIR USE IN TREATING AUTOIMMUNE AND INFLAMMATORY DISORDERS The present invention relates to antibodies that specifically bind to IL12Rβ1, the non-signal transducing chain of both the heterodimeric IL12 and IL23 receptors. The invention more specifically relates to specific antibodies that are IL12 and IL23 receptor antagonists... | 04/05/2012 |
| 20120083587 | BIOLOGICALLY ACTIVE POLYPEPTIDES DERIVED FROM A NOVEL EARLY STAGE PREGNANCY FACTOR DESIGNATED MATERNIN (MA) The invention relates to therapeutic polypeptides isolated from beta-human chorionic gonadotropin (β-hCG) found in human early pregnancy urine, now synthetically produced and designated Maternin. The therapeutic polypeptides and their functional equivalents are useful ... | 04/05/2012 |
